Pfizer Putting On The Pressure, But AstraZeneca Still Hard To Get
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer execs speak of complementary drug portfolios and pipelines. Market watchers, however, believe the merger interest is driven more by financial rationale: a lower corporate tax rate, a way to use ex-U.S. cash and the likelihood of significant synergies. U.K. law sets May 26 deadline for a new bid.
You may also be interested in...
Pfizer’s Latest Palbociclib Data Could Mean Slimmer Lead Over CDK4/6 Rivals
Final Phase II data for palbociclib in breast cancer at AACR meeting raise questions about prospects for accelerated approval prior to Phase III results. Meanwhile, Lilly’s bemaciclib emerges as potent monotherapy with seemingly lower risk for neutropenia, but more data are needed to flesh out the drug’s profile.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.